

# BRICS Vaccine R&D Center

## ISSUES NOTE

### BRICS 2025



#### 1. Background Information

Since 2018, BRICS leaders have committed to enhancing cooperation in vaccine research and development, starting with the endorsement of the establishment of the BRICS Vaccine R&D Center during the South African Summit. This commitment was reaffirmed in the 2020 Moscow Declaration, which emphasized the importance of timely and effective operationalization. By 2021, each BRICS country had designated national centers to contribute to this initiative under India's leadership. In 2022, China hosted an online launch ceremony and workshop on vaccine cooperation, marking a significant milestone in the center's operationalization. Most recently, in 2024, Russia hosted a meeting focused on the functioning of the BRICS Vaccine Center, further solidifying its role as a platform for collaborative vaccine research and development.

The Center aims to leverage BRICS countries' complementary advantages in vaccine research and development, enhance their capacity to prevent and control infectious diseases, and provide timely assistance to other developing countries in need. It is expected to prioritize joint vaccine research and development, facilitate information and knowledge sharing, support collaborative projects among BRICS countries, and promote inclusive distribution and use of vaccines to ensure accessibility and affordability.

#### 2. Priorities

2.1. Foster the creation of the Electronic R&D Stock proposed by Russia during its 2024 chairship.

2.2. Provide consulting services for vaccine market stakeholders in BRICS countries through the Stock platform.

2.3. Promote bilateral partnerships in vaccine development among BRICS countries as an initial step.

2.4. Encourage partnerships among members of the Vaccine R&D Centers and between other Centers and Networks formally established by BRICS.

2.5. Facilitate the participation of the New Development Bank in discussions related to the Vaccine R&D Center to establish financing mechanisms for its projects.

2.6. Key services/categories:

- Research & development, including development of biotechnological products;
- Laboratory and instrumental testing;
- Preclinical trials;
- Buying/selling technology;

- Procurement of equipment, reagents, and other necessary materials
- Miscellaneous biotechnology services.



COOPERATING FOR AN INCLUSIVE AND SUSTAINABLE WORLD